CIBC Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

CIBC Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$287K	Buy	14,265 +140	+1%	+$2.52K	﹤0.01%	1051
2026 Q2	$245K	Sell	14,125 -130	-0.9%	-$1.78K	﹤0.01%	1180
2026 Q1	$177K	Buy	+14,255	New	+$191K	﹤0.01%	1252
2022 Q4	–	Sell	-14,567	Closed	-$29K	–	1071
2022 Q3	$29K	Hold	14,567	–	–	﹤0.01%	1228
2022 Q2	$46K	Sell	14,567 -1,066	-7%	-$3.86K	﹤0.01%	1236
2022 Q1	$65K	Hold	15,633	–	–	﹤0.01%	1481
2021 Q4	$75K	Buy	15,633 +1,395	+10%	+$6.96K	﹤0.01%	1504
2021 Q3	$76K	Buy	14,238 +2,024	+17%	+$10.2K	﹤0.01%	1435
2021 Q2	$63K	Hold	12,214	–	–	﹤0.01%	1354
2021 Q1	$82K	Sell	12,214 -52	-0.4%	-$288	﹤0.01%	1310
2020 Q4	$56K	Hold	12,266	–	–	﹤0.01%	1228
2020 Q3	$48K	Buy	12,266 +304	+3%	+$1.3K	﹤0.01%	1103
2020 Q2	$57K	Hold	11,962	–	–	﹤0.01%	1060
2020 Q1	$42K	Hold	11,962	–	–	﹤0.01%	980
2019 Q4	$58K	Buy	+11,962	New	+$41.6K	﹤0.01%	1164

Other funds holding AMRX

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Tucker Asset Management Littleton, Colorado $406M AUM 20.49% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

CIBC Asset Management's AMRX Position: Q3 2026 in Review

CIBC Asset Management increased its Amneal Pharmaceuticals (AMRX) stake by 0.99% in Q3 2026, buying an estimated $2.52K and bringing the position to 14,265 shares worth $287K. The position accounts for ﹤0.01% of the portfolio, ranked #1051.

CIBC Asset Management first reported a position in AMRX in Q4 2019 and has held it in 15 quarters since. 146 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.

CIBC Asset Management held 14,265 shares of Amneal Pharmaceuticals worth $287K as of Q3 2026.
CIBC Asset Management bought 140 Amneal Pharmaceuticals shares in Q3 2026, an estimated $2.52K.
Amneal Pharmaceuticals made up ﹤0.01% of CIBC Asset Management's portfolio in Q3 2026, its #1051 holding.
CIBC Asset Management first reported a position in Amneal Pharmaceuticals in Q4 2019 and has held it in 15 quarters since.
146 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.

Based on CIBC Asset Management's 13F filing for Q3 2026, filed 5 Nov 2026.